随着三代 EGFR 酪氨酸激酶抑制剂（TKI）在 EGFR 突变非小细胞肺癌（NSCLC）一线治疗中应用增多，其耐药机制日益明晰。克服耐药策略也在不断发展，多种方案迎来获批。现笔者就将三代 EGFR-TKI 耐药机制和应对策略进行总结。01三代 ...

癌度医学临床招募资讯微信群（点击）癌度选择这个题目和相关文献编译内容，是为了基因突变全阴性的肺腺癌患者作为一个启示。并让我们更加客观地看待基因检测技术，基因检测的结果是肺癌患者靶向药、免疫治疗药物的参考依据，但是不应该成为绝对的“判决书”，尤其是全阴 ...

Dizal will also present results from the ongoing Phase I/II study of DZD6008, a 4th generation EGFR TKI with full BBB penetration, in advanced EGFR mutation positive (EGFRm) non-small cell lung cancer ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

A healthy 36-year-old non-smoker from the UK, was misdiagnosed with anxiety for months before discovering he had terminal ...

EGFR is a gene involved in cell growth and division. Mutations in this gene are linked with lung cancer. Up to a third of all lung cancer cases have a gene mutation present. T790M is an EGFR ...

"The FLAURA data for osimertinib are likely to result in a major paradigm shift in the treatment of patients with EGFR mutation-positive advanced lung cancer. Not only did the trial demonstrate a ...

"Targeting agrin is expected to fill a major gap in boosting the effectiveness of EGFR therapies, thereby reducing the risk of lung cancer relapse," says Dr. Chakraborty. Using lung cancer cell ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

The continued overall survival trend seen here at ELCC in the unresectable Stage III setting and the promising data for combinations that can address progression in the advanced setting, together ...

The global Osimertinib drugs market is on the verge of significant expansion, with an estimated rise in revenue from US$ 4,828.6 million in 2021 to US$ 11,829.8 million by 2027. This growth reflects a ...